This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of California, Davis
ClinicalTrials.gov Identifier:
NCT01869634
First received: June 1, 2013
Last updated: May 24, 2017
Last verified: May 2017
June 1, 2013
May 24, 2017
June 2013
December 2016   (Final data collection date for primary outcome measure)
Recovery of CD4 T-lymphocytes in GALT [ Time Frame: 12 months ]
CD4+ T-cells in the lamina propria/mm2 before and after 12 months of therapy compared to age-matched control volunteers without HIV.
Recovery of CD4 T-lymphocytes in GALT [ Time Frame: 12 months ]
To quantify restoration of GALT Lymphocyte Populations following Darunavir Therapy as measured by CD4+ T-cells in the lamina propria/mm2 before and after 12 months of therapy compared to age-matched control volunteers without HIV.
Complete list of historical versions of study NCT01869634 on ClinicalTrials.gov Archive Site
To measure the change in cardiovascular risk [ Time Frame: 12 months ]
computerized axial tomography angiography of the coronary arteries (CT-angio) before and after 12-months of Darunavir therapy
To measure the change in cardiovascular risk [ Time Frame: 12 months ]
To measure the change in CVD risk as determined by Intimal Medial Thickness (IMT), Brachial Artery Reactivity (BAR), and computerized axial tomography angiography of the coronary arteries (CT-angio) before and after 12-months of Darunavir therapy and in comparison to age-matched and traditional CVD risk parameters-matched control volunteers without HIV.
changes in systemic immune activation [ Time Frame: 12 months ]
decline in plasma cytokine levels (IL-6)
changes in systemic immune activation [ Time Frame: 12 months ]
To determine correlations between Immune Activation and Metabolic Profile as measured by CD38/HLA-DR co-expression on CD4+ and CD8+ lymphocytes in the PBMC's, and duodenal GALT and inflammatory cytokines in plasma and tissue before and after 12-months of Darunavir therapy and in comparison to age-matched control volunteers without HIV.
 
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation (CD)4+ T-cell populations, normalization of systemic immune activation, and improved HIV-associated cardiovascular disease (CVD) risk.
Rationale Infection with HIV causes significant morbidity and mortality, even among individuals who are virologically suppressed with combination anti-retroviral therapy (ART). ART is effective in prolonging life and enabling individuals who are HIV positive to live near-normal life spans. However, these individuals are increasingly developing a number of chronic diseases of aging, such as atherosclerotic cardiovascular disease (ASCVD). The proposed studies will examine the role of highly active antiretroviral therapy in restoring the mucosal immunity and the systemic effect on immune activation, bacterial translocation, and change in HIV-associated cardiovascular disease risk.
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Human Immunodeficiency Virus Infection
Drug: darunavir with ritonavir and fixed-dose viread+emtricitabine daily
Other Name: darunavir (Prezista®) 800 mg with ritonavir 100 mg and Truvada® to be taken once daily
  • Active Comparator: HIV positive naive to ART
    HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
    Intervention: Drug: darunavir with ritonavir and fixed-dose viread+emtricitabine daily
  • No Intervention: normal control volunteers
    HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
37
December 2016
December 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Willing to sign consent form
  • Naïve to ART (remote ART use >5 years will be considered on a case by case basis)
  • No known GI or cardiovascular disease
  • Between the ages of 18 and 60
  • No active opportunistic infections or therapy for acute OI within 30 days of entry. Subjects can be on secondary prophylaxis with a history of AIDS defining illness.
  • All women of childbearing potential (WCBP) must have a negative urine pregnancy test before any of the invasive or radiation exposure study procedures.
  • Normal population should be free of chronic metabolic conditions such as diabetes, hypercholesterolemia, or coronary artery disease
  • There are no CD4+ T-cell count or HIV plasma viral load restrictions.

Exclusion Criteria:

  • Abnormal coagulation parameters (PT>1.2 upper limit of normal (ULN))
  • Thrombocytopenia (platelet count <50.000 within 6 weeks)
  • Contra-indications to upper endoscopy or conscious sedation
  • Anemia (>grade 1 [appendix 1])
  • Aspirin, ibuprofen, warfarin or other agents that interfere with the coagulation cascade are prohibited within 1 week of endoscopy.
  • Renal insufficiency (serum Creatinine >1.2 ULN)
  • History of chronic proteinuria that could impact viread use.
  • Allergy to contrast used for CT angiography
  • Requirement to take medications that are contraindicated with study ART regimen.
Sexes Eligible for Study: All
21 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01869634
394080
IIS RFA _Asmuth:TMC114HIV2029 ( Other Identifier: Other )
No
Not Provided
Not Provided
University of California, Davis
University of California, Davis
Not Provided
Not Provided
University of California, Davis
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP